Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial - Report - MDSpire
Advertisement
Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial
Clinical Report: Assessment of MuShengshu for Mild to Moderate Atopic Dermatitis
Overview
This report outlines a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of MuShengshu in patients with mild-to-moderate atopic dermatitis (AD). The study aims to provide high-quality evidence regarding the use of this traditional Chinese herbal bath solution in conjunction with foundational therapies.
Background
Atopic dermatitis is a common chronic inflammatory skin condition that significantly affects patients' quality of life. Current treatment options have limitations, including side effects and insufficient efficacy. The exploration of alternative therapies, such as MuShengshu, may offer new avenues for effective management of AD.
Data Highlights
No numerical data available as this is a protocol report.
Key Findings
The study will enroll 66 patients with mild-to-moderate AD.
Participants will be randomly assigned to receive either MuShengshu or a placebo for 4 months.
The primary outcome is the proportion of patients achieving ≥50% improvement in the Eczema Area and Severity Index (EASI) score at week 4.
Secondary outcomes include assessments of EASI, Visual Analogue Scale (VAS), Investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI).
Data analysis is scheduled to begin in August 2026, with preliminary results expected by December 2026.
Clinical Implications
The findings from this trial may support the integration of traditional Chinese herbal solutions into the treatment regimen for atopic dermatitis. Clinicians should remain informed about emerging therapies that may enhance patient outcomes in managing this chronic condition.
Conclusion
The ongoing study of MuShengshu aims to fill the gap in high-quality evidence for alternative therapies in atopic dermatitis management. Results may contribute to improved treatment strategies for patients with this challenging skin condition.
